The study of neglected diseases such as Chagas is essential because of the disproportionate impact these diseases have on vulnerable populations. Research in this field is crucial to understand underlying mechanisms, develop more effective and accessible treatments, as well as to refine new diagnostic methods. Within this context, LNBio is working to investigate new therapeutic targets and biomarkers.
Using advanced techniques like molecular synthesis, enzymatic and cell assays, calorimetry, and X-ray diffraction, LNBio identifies inhibitor binding sites and the crystal structure of target proteins. These initiatives are intended to develop innovative therapies and improve public health, directly benefiting the populations affected by these diseases.
